STOCK TITAN

Immunome holder plans $334K Rule 144 stock sale

Form 144 reports Jack P. Higgins’ planned Rule 144 sale of 13,200 Immunome common shares obtained via stock option exercise.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Immunome Inc. (IMNM) received a notice that Jack P. Higgins plans to sell up to 13,200 shares of common stock under Rule 144, with Fidelity Brokerage Services LLC acting as broker. The shares relate to a stock option exercise from September 10, 2025, paid in cash.

The filing lists Immunome common stock as quoted on NASDAQ and reports 113,577,629 shares of common stock outstanding, serving as the baseline for this planned sale.

Positive

  • None.

Negative

  • None.
Shares to be sold under Rule 144 13,200 shares Maximum Immunome common shares covered by Jack P. Higgins’ Form 144 notice
Shares outstanding 113,577,629 shares Immunome common stock outstanding as referenced in the Form 144
Aggregate market value of securities to be sold $334,224.00 Value associated with the 13,200 Immunome shares listed in the securities information section
Stock option exercise date September 10, 2025 Date on which the 13,200 shares were acquired via stock option exercise for cash
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common | 09/10/2025 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jack P. Higgins"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Immunome Inc. (IMNM)'s latest Form 144 disclose?

It discloses that Jack P. Higgins plans to sell up to 13,200 shares of Immunome Inc. common stock under Rule 144, with Fidelity Brokerage Services LLC as broker. The shares are tied to a stock option exercise completed on September 10, 2025.

How many Immunome (IMNM) shares are covered by this Rule 144 notice?

The notice covers up to 13,200 shares of Immunome common stock for potential sale. These shares stem from a stock option exercise and are to be sold through Fidelity Brokerage Services LLC under Rule 144.

How were the Immunome (IMNM) shares in this Form 144 acquired?

The shares were acquired through a stock option exercise on September 10, 2025, with the consideration described as cash. The issuer in the acquisition entry is listed as Immunome Inc.

Who is the broker for the planned Immunome (IMNM) share sale?

The broker is Fidelity Brokerage Services LLC, listed with its Smithfield, Rhode Island address. The Form 144 is signed by Wade Moss as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jack P. Higgins.

How many Immunome (IMNM) shares are reported outstanding in the Form 144?

The filing reports 113,577,629 shares of Immunome common stock outstanding. This figure provides context for the 13,200 shares covered by the Rule 144 notice, which represent a small portion of the total outstanding shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading